Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
06/2005
06/16/2005WO2004098536A3 Anti-viral activity of cathelicidin peptides
06/16/2005WO2004091548A3 Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
06/16/2005WO2004084825A3 Wound healing composition derived from low platelet concentration plasma
06/16/2005WO2004084816A3 IMPROVED CD4-IgG2 FORMULATIONS
06/16/2005WO2004084804A3 Detection and monitoring of lung cancer
06/16/2005WO2004071400A3 Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
06/16/2005WO2004069159A3 Vitamin receptor binding drug delivery conjugates
06/16/2005WO2004069144A8 Method for decreasing nicotine and other substance use in humans
06/16/2005WO2004060280A3 Methods and compositions for inhibiting the growth of hematopoietic malignant cells
06/16/2005WO2004052305A3 Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
06/16/2005WO2004050013A3 Material compositions and related systems and methods for treating cardiac conditions
06/16/2005WO2004037195A3 Treatment of diabetes
06/16/2005WO2004035006A3 Methods and compositions for immunization against hiv
06/16/2005US20050131237 Indole derivatives
06/16/2005US20050131224 Method for preparing radiolabeled thymidine
06/16/2005US20050131223 Method for preparing radiolabeled thymidine having low chromophoric byproducts
06/16/2005US20050131161 Process for removing bile salts from a patient and alkylated compositions therefor
06/16/2005US20050131138 Drug; therapy for kidney disease; removal of phosphates; gastrointestinal disorders
06/16/2005US20050131067 Novel polymorphs of tolterodine tartrate
06/16/2005US20050131028 Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
06/16/2005US20050130993 Synthesis and purification of valacyclovir
06/16/2005US20050130976 Bicyclic inhibitors of MEK and methods of use thereof
06/16/2005US20050130972 Derivatives have a positive charge at the position corresponding to the anomeric position of a pyranose ring; active-site specific chaperones for mutant glucocerebrosidase
06/16/2005US20050130971 Cyclooxygenase inhibitors are chromene derivative compounds, benzothiopyrans, dihydroquinolines, dihydronaphthalenes; phosphodiesterase inhibitors are tricyclic sulfonamide derivatives
06/16/2005US20050130959 Selective in presence of at least one other cathepsin isozyme; such as (3-cyclopentyl-{[5-(3-fluoro-phenyl)-furan-2-carbonyl]-amino}-propionylamino)-4-oxo-butyric acid
06/16/2005US20050130954 Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline
06/16/2005US20050130943 Bicyclic inhibitors of MEK and methods of use thereof
06/16/2005US20050130906 Amelioration of macular degeneration and other ophthalmic diseases
06/16/2005US20050130189 Using chromic visceral hypersensitivity (CVH) polypeptide concentration as diagnostic tool in detection of inflammatory disorders
06/16/2005US20050129727 Drug core encapsulated with multilayer polyelectrolyte shells
06/16/2005US20050129682 Receptor for Advanced Glycation Endproducts (RAGE); rheumatoid arthritis; solubility
06/16/2005US20050129610 Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor
06/16/2005DE10353196A1 Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix Multilayer dosage form with the delivery of a modulatory substance influencing matrix
06/16/2005CA2549158A1 Methods of generating stem cells and embryonic bodies carrying disease-causing mutations and methods of using same for studying genetic disorders
06/16/2005CA2547652A1 Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal
06/16/2005CA2547356A1 Diamine and iminodiacetic acid hydroxamic acid derivatives
06/16/2005CA2547066A1 Advanced indolinone based protein kinase inhibitors
06/16/2005CA2546437A1 Preparing individualized dosage forms of medicaments
06/16/2005CA2537029A1 Micellar systems useful for delivery of lipophilic or hydrophobic compounds
06/16/2005CA2536393A1 Use of liposomes which are small unilamellar vesicles for the removal of an entity from a biological sample
06/15/2005EP1541673A1 Novel probiotics for pet food applications
06/15/2005EP1541170A1 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
06/15/2005EP1540743A2 Light emitting diode, support & method of manufacture
06/15/2005EP1540520A2 Method, routines and system for identification of imprints on dosage forms
06/15/2005EP1540335A2 Screening methods for cognitive enhancers
06/15/2005EP1539990A2 PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE
06/15/2005EP1539799A2 Crosslinked compounds and methods of making and using thereof
06/15/2005EP1539749A2 Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
06/15/2005EP1539714A2 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors
06/15/2005EP1539252A2 Blood clot-targeted nanoparticles
06/15/2005EP1539247A2 Alpha 5 beta 1 and its ability to regulate the cell survival pathway
06/15/2005EP1539241A2 Method of controlling pharmacokinetics of immunomodulatory compounds
06/15/2005EP1539237A2 Humanized antibodies against human 4-1bb
06/15/2005EP1539229A2 Vaccines containing viruses involved in avian malabsorption syndrome and methods of administration therefor
06/15/2005EP1539228A2 Novel composition and methods for the treatment of immune related diseases
06/15/2005EP1538973A2 Delivering compounds to the brain by modifying properties of the bbb and cerebral circulation
06/15/2005EP1538903A2 Method of treating diabetes and related conditions
06/15/2005EP1538900A2 Cancer vaccines containing epitopes of oncofetal antigen
06/15/2005EP1435937B1 Composition comprising paracetamol and a bitterness masking component
06/15/2005EP1248785B1 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
06/15/2005EP1150973B1 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
06/15/2005EP0991654B1 Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and compositions containing same
06/15/2005CN1626516A Novel intermediate for prepn. of pyrazolopyrimidinones
06/15/2005CN1626238A Composition of multiple scattered mixture contg.polypeptide and its pharm compsn.
06/15/2005CN1205964C Medicament for curing colpitismycotica and trichomonal vaginitis and its preparation method
06/15/2005CN1205937C Phosphatidic acid-comprising compositions
06/15/2005CN1205920C Leave-on antimicrobial compositons
06/15/2005CN1205914C Cosmetic composition
06/15/2005CN1205912C Antiperspirant compositions
06/14/2005US6906088 Taxanes having a carbamoyloxy substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substitutions; anticarcinogenic agent
06/14/2005US6906048 N-acetylcolchinol-O-phosphate combination therapies with vascular damaging activity
06/14/2005US6906044 Regeneration of articular cartilage damaged by grade I and II osteoarthritis by means of the intraarticular application of a mixture of sodium hyaluronate and chondroitin sulfate in a gel vehicle
06/09/2005WO2005052134A2 Ttbks as modifiers of the beta catenin pathway and methods of use
06/09/2005WO2005052132A2 Mbms as modifiers of branching morphogenesis and methods of use
06/09/2005WO2005052131A2 C140rf35 as modifier of the beta catenin pathway and methods of use
06/09/2005WO2005051906A2 Heterocyclic inhibitors of mek and methods of use thereof
06/09/2005WO2005051331A2 Chaperone-based therapy for niemann-pick disease
06/09/2005WO2005051330A2 METHOD FOR TREATING HUMAN TUMOR CELLS WITH A NEWCASTLE DISEASE VIRUS STRAIN HAVING A p53 INDEPENDENT ONCOLYTIC EFFECT
06/09/2005WO2005051329A2 Systems and methods for altering vestibular biology
06/09/2005WO2005051328A2 Amelioration of macular degeneration and other ophthalmic diseases
06/09/2005WO2005051327A2 Glycopegylated erythropoietin
06/09/2005WO2005051326A2 Treatment of a condition in a mammal with administration of compounds and methods of use thereof
06/09/2005WO2005051325A2 Carvedilol compositions methods of treatment and delivery
06/09/2005WO2005051324A2 Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
06/09/2005WO2005051322A2 Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts
06/09/2005WO2005051321A2 Treatment of inflammatory bowel disease through induction of indoleamine 2,3-dioxygenase
06/09/2005WO2005051320A2 Gcks as modifiers of branching morphogenesis and methods of use
06/09/2005WO2005051319A2 Plks as modifiers of the beta catenin pathway and methods of use
06/09/2005WO2005051318A2 Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
06/09/2005WO2005051317A2 Substituted imidazo ring systems and methods
06/09/2005WO2005051315A2 On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
06/09/2005WO2005051314A2 Iraks as modifiers of branching morphogenesis and methods of use
06/09/2005WO2005051313A2 Methods and reagents for treating, preventing and diagnosing bunyavirus infection
06/09/2005WO2005051312A2 Extracorporeal pathogen reduction system
06/09/2005WO2005051311A2 Enuresis device with magnetic fastener
06/09/2005WO2005051310A2 Ctpss as modifiers of the pten pathway and methods of use
06/09/2005WO2005051309A2 Systems and methods for measuring tear film osmolarity
06/09/2005WO2005051308A2 Methods of treating diseases and disorders by targeting multiple kinases
06/09/2005WO2005051307A2 Epha2 agonistic monoclonal antibodies and methods of use thereof
06/09/2005WO2005051306A2 Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease
1 ... 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 ... 295